Sandoz Group AG (STU:D8Y) Total Receivables: €2,226 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:D8Y Sandoz Group AG STU:D8Y
39 GF Score
Price €77.16
GF Value €51.27
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Total Receivables?

Sandoz Group AG STU:D8Y -0.85% 39 Total Receivables is €2,226 Mil as of Jun. 2026. GuruFocus rates STU:D8Y with a GF Score™ of 39/100 and a GF Value™ of €51.27 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sandoz Group AG's Total Receivables for the quarter that ended in Jun. 2026 was €2,226 Mil.

Sandoz Group AG Total Receivables Related Terms

Sandoz Group AG Total Receivables Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Total Receivables Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Receivables
3,264.35 2,780.34 3,004.43 2,366.43

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Receivables Get a 7-Day Free Trial 2,434.91 3,004.43 2,006.24 2,366.43 2,226.42
STU:D8Y
39GF Score
Sandoz Group AG STU:D8Y
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €2,226 Mil mean?
Sandoz Group AG (STU:D8Y) has a Total Receivables of €2,226 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Total Receivables too high?
Sandoz Group AG's current Total Receivables is €2,226 Mil. Overall, Sandoz Group AG has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Total Receivables compare to ZTS and UTHR?
Sandoz Group AG's Total Receivables of €2,226 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Total Receivables is €2,226 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (STU:D8Y) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.27, compared to a current price of €77.16 — trading 50.5% above its estimated fair value. The current Total Receivables is €2,226 Mil. Sandoz Group AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Sandoz Group AG (STU:D8Y), the current Total Receivables is €2,226 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sandoz Group AG (STU:D8Y) Overvalued in 2026?

Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued. The current stock price of €77.16 is trading 50.5% above its estimated GF Value™ of €51.27. GuruFocus considers Sandoz Group AG to be Significantly Overvalued.

Key valuation signals for STU:D8Y:

  • Total Receivables: €2,226 Mil
  • GF Value™: €51.27 vs. price of €77.16 (50.5% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the STU:D8Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
39GF Score

Get the complete analysis for STU:D8Y

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.16
Price
€51.27
GF Value